AstraZeneca’s Type 2 Diabetes Treatment Shows Clinical Benefit In Adolescents
AstraZeneca Plc (NASDAQ:AZN) has reported results from the Phase 3 trial evaluating exenatide extended-release 2mg in adolescents aged 10–17 years with…
Sickle Cell Biotech, Graphite Bio Prices Upsized Initial Public Offering
Graphite Bio Inc (NASDAQ:GRPH) is set to go public on the heels of a $238 million raise less than ten months…
Vir Biotech’s HBV Candidates Show Positive Safety Profiles
Vir Biotechnology Inc (NASDAQ:VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of…
Regulus Therapeutics Presents Additional Data From Rare Kidney Disease Program
Regulus Therapeutics Inc (NASDAQ:RGLS) announced the presentation of additional data from the first cohort from Phase 1b trial of RGLS4326 for…
Alzheimer’s Biotech Acumen Pharmaceuticals Prices $125M IPO Soon After Biogen’s Aduhelm Approval
Acumen Pharmaceuticals Inc has set the terms for its IPO to raise around $125 million to take ACU193, an antibody against amyloid-beta oligomers, to the end of phase 2 in Alzheimer’s disease.
FDA To Miss Action Dates For AbbVie’s Upadacitinib Application For Psoriatic Arthritis, Ankylosing Spondylitis
The FDA will not meet action dates for AbbVie Inc’s (NYSE:ABBV) supplemental marketing applications for Rinvoq (upadacitinib) for active psoriatic arthritis and…
EMA’s Advisory Committee Backs Approval Of BioMarin’s Dwarfism Candidate
European Medical Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the…
Ampio’s Phase 2 Study Of Inhaled Ampion In COVID-19 Patients Gets Underway
Ampio Pharmaceuticals, Inc. (NYSE: AMPE) announced an update to its COVID-19 program that is evaluating its lead asset Ampion.
Mirati’s KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation
The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Inc’s (NASDAQ:MRTX) adagrasib in non-small cell lung cancer (NSCLC) patients with the…
Pieris Stock Moves Higher On €14.2M Grant For PRS-220 In Post-COVID Pulmonary Fibrosis
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor…